What's in Stephen Chan Lam's pipeline?

Stephen Chan Lam has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Stephen Chan Lam's portfolio?

Top competitors by shared drug class: CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Nanfang Hospital, Southern Medical University, Sun Yat-sen University, University of Florida.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/stephen-chan-lam.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Stephen Chan Lam — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stephen Chan Lam pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 shared drug class
Nanfang Hospital, Southern Medical University · 1 shared drug class
Sun Yat-sen University · 1 shared drug class
University of Florida · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Stephen Chan Lam:

Cite this brief

Drug Landscape (2026). Stephen Chan Lam — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/stephen-chan-lam. Accessed 2026-05-16.